Lu'e Biyan Formula for Treatment of Allergic Rhinitis Patients with Fei (Lung)-Qi Deficiency-Coldness Syndrome: A Randomized, Double Blind, and Placebo-Controlled Trial.
10.1007/s11655-025-3948-0
- Author:
Ming-Yue JIA
1
;
Mei-Yi ZHANG
2
;
Si-Yao XIAO
1
;
Yang YU
1
;
Xiang SHAO
1
;
Chun-Sheng HAN
1
;
Gui-Ling HAN
3
,
4
Author Information
1. Department of Pulmonary and Critical Care Medicine/Department of Integrated Traditional Chinese and Western Medicine for Pulmonary Diseases Part 1, National Center for Integrative Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital; National Center for Respiratory Medicine; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, National Clinical Research Center for Respiratory Diseases, Beijing, 100029, China.
2. Graduate School of Beijing University of Chinese Medicine, Beijing, 100029, China.
3. Department of Pulmonary and Critical Care Medicine/Department of Integrated Traditional Chinese and Western Medicine for Pulmonary Diseases Part 1, National Center for Integrative Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital; National Center for Respiratory Medicine; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, National Clinical Research Center for Respiratory Diseases, Beijing, 100029, China. hjxdehan@
4. com.
- Publication Type:Randomized Controlled Trial
- Keywords:
Chinese medicine;
Fei (Lung)-qi deficiency-coldness syndrome;
Lu’e Biyan Formula;
allergic rhinitis;
randomized controlled trial
- MeSH:
Humans;
Drugs, Chinese Herbal/therapeutic use*;
Male;
Rhinitis, Allergic/drug therapy*;
Female;
Adult;
Double-Blind Method;
Quality of Life;
Qi;
Middle Aged;
Loratadine/therapeutic use*;
Medicine, Chinese Traditional;
Syndrome;
Lung/drug effects*;
Young Adult;
Treatment Outcome
- From:
Chinese journal of integrative medicine
2025;31(11):1029-1036
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To observe the clinical effect and safety of Lu'e Biyan Formula (LBF) combined with loratadine in the treatment of moderate to severe allergic rhinitis (AR) patients with Fei (Lung)-qi deficiency-coldness (FQDC) syndrome.
METHODS:From September 2023 to December 2024, moderate to severe AR patients with FQDC syndrome were recruited from the Outpatient Department of Integrated Traditional Chinese and Western Medicine for Pulmonary Diseases Part 1, China-Japan Friendship Hospital. Participants were randomly assigned to a test group and a control group by using a random number table at a ratio of 1:1. Both groups received oral loratadine tablets (10 mg, once daily) for 2 weeks. In addition, the test group received oral LBF (30 mL, twice daily), and the control group received a placebo of LBF. Changes in the Total Nasal Symptom Score (TNSS), Total Non-nasal Symptom Score (TNNSS), Visual Analog Scale (VAS), Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), and Chinese medicine (CM) syndrome scores before and after treatment were compared between groups. Moreover, the total effective rates and disease recurrence rates were compared. Adverse events (AEs) during the study period were also recorded.
RESULTS:Totally 109 participants were recruited, and the full analysis set included 105 cases, 54 in the test group and 51 in the control group. Compared with the pre-treatment values, the scores of sneezing, runny nose, nasal obstruction, nasal itching, TNSS, TNNSS, VAS, RQLQ, and CM syndrome were significantly reduced in both groups at 1 and 2 weeks post-treatment and 12 weeks post-drug withdrawal (P<0.01). After treatment, the aforementioned scores in the test group were all markedly lower than those in the control group (P<0.01). Moreover, the total effective rate in the test group was higher than that in the control group (98.15% vs. 70.59%, P<0.01). After 12 weeks of drug withdrawal, there was no significant difference in the recurrence rate between groups (13.21% vs. 22.22%, P>0.05). No obvious AEs were observed in either group following treatment.
CONCLUSIONS:The combination of LBF with loratadine can effectively alleviate the symptoms of moderate to severe AR patients with FQDC syndrome, thereby improving their quality of life. This therapy demonstrated both precise effect and high safety. (Trial registration No. ITMCTR2025000589).
